BIND Therapeutics, a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins, has entered into a research agreement with Roche to discover novel nanomedicines using Accurins for the treatment of diseases in therapeutic areas outside of oncology. The collaboration will focus on combining BIND's Accurin technology with Roche's proprietary therapeutic payloads and targeting ligands.

"The addition of Roche, a global leader and innovator, to our family of collaborators underscores BIND's unique position in nanomedicine," said Scott Minick, CEO of BIND Therapeutics. "By combining BIND's Medicinal Nanoengineering platform with Roche's experience in disease areas with high unmet medical need, this agreement further validates the wide-ranging potential for our technology and facilitates extending our platform into new therapeutic areas."